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Summary
In patients with early stage papillary thyroid carcinoma (PTC) who
have had a thyroidectomy, the decision must be made to accept or
reject radioactive iodine remnant ablation (RRA). Counselling
patients about this decision can be challenging, given the medical
evidence uncertainties and the complexity of related information.
Although physicians are the primary source of medical information
for patients considering RRA, some patients have a desire for sup-
plemental information from sources such as the internet. Yet, thy-
roid cancer resources on the internet are of variable quality, and
some may not be applicable to the individual case. We have devel-
oped a computerized educational tool [called a decision aid (DA)],
directed to patients with early stage papillary thyroid cancer, and
intended as an adjunct to physician counselling, to relay evidence-
based medical information on disease prognosis and the choice to
accept or reject RRA. DAs are tools used to inform patients about
available treatment options and have been utilized in oncologic
decision-making. We tested our web-based DA in ﬁfty patients
with early stage PTC and found that it improved medical knowl-
edge. Furthermore, participants found the technical usability of the
tool acceptable. We are currently conducting a randomized con-
trolled trial comparing the use of the DA plus usual care to usual
care alone to conﬁrm the educational beneﬁt of the website and
examine its impact on the decision-making process. In the future,
DAs may play an expanded role as an adjunct to physician counsel-
ling in the care of patients with thyroid cancer.
(Received 22 November 2010; returned for revision 5 December
2010;ﬁnally revised15December2010;accepted19December2010)
Introduction
Thyroid carcinoma is increasingly being diagnosed
1–5, and the
most common subtype is papillary thyroid carcinoma (PTC).
1,6
New cases of PTC are most commonly diagnosed at an early stage,
with a low risk of disease-related mortality.
7 After the standard sur-
gical removal of the thyroid (total or near-total thyroidectomy),
radioactive iodine remnant ablation (RRA) treatment or no RRA
(with close medical follow-up) is considered acceptable options for
management of early stage PTC, with some ﬂexibility in the
approach depending on the individual case characteristics and
treatment preferences.
8
Information needs of patients with thyroid cancer
considering RRA
Decision-making about accepting or rejecting RRA for early stage
PTC is challenging, as there are no published randomized con-
trolled trials testing the beneﬁt of this intervention on long-term
thyroid cancer outcomes, and results from existing observational
medical evidence are conﬂicting.
9 In a recent qualitative study, thy-
roid cancer survivors identiﬁed some key medical information
needs related to the consideration of RRA (or no RRA), and these
include the following: information on the disease prognosis, clearly
delineated treatment options (RRA or no RRA, with follow-up
implications), the treatment rationale, the potential risks and bene-
ﬁts of the treatment options and related medical evidence uncer-
tainties, current clinical practice guideline recommendations and
reproductive considerations (for some patients) (Table 1).
10 The
desired level of detail of medical information and the degree of
involvement in medical decision-making is highly variable among
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 2011 Blackwell Publishing Ltd 419patients with thyroid cancer, with the spectrum spanning from the
preference for basic medical information and leaving decisions
entirely to the physician, to the preference of highly detailed infor-
mation and active participation in decision-making.
10 The infor-
mation needs of some patients with thyroid cancer may not be fully
met in their clinical encounter with their healthcare providers.
10
For patients with thyroid cancer desiring additional medical infor-
mation to supplement physician counselling, the internet is easily
accessible resource, but unfortunately, the information retrieved
may not necessarily be applicable to the individual case.
10 Thus,
thyroid cancer survivors have called for the development of a
plain-language educational resource, called a decision aid (DA),
relating to the decision to accept or reject RRA.
10 The availability of
a web-based DA, with the capacity to retrieve printed material, has
been favoured by thyroid cancer survivors.
10
The use of DAs in medical decision-making
Decision aids are tools or instruments used to inform patients
about available treatment options, including evidence about poten-
tial beneﬁts and risks of interventions.
11 DAs facilitate evidence-
based patient choice
12–14 and are useful in the clinical setting when
there is more than one treatment option.
15 In a recent systematic
review, DAs were reported to improve patient knowledge, result in
more accurate risk perceptions, increase the proportion of people
active in decision-making and reduce decisional conﬂict, when
compared to usual care.
16 Also, in another systematic review, can-
cer-related DAs increased patients’ knowledge compared to usual
practice, without increasing anxiety.
17 However, DAs relating to
thyroid cancer care have been lacking.
The development of a DA on consideration of RRA (or
no RRA) in early stage PTC
Werecentlydevelopeda patient-directed computerizedDA explain-
ing the decision to accept or reject RRA for treatment of early
stage PTC.
18 This DA is intended to be used as an adjunct to
individualized physician counselling. This DA explains the follow-
ing concepts relating to RRA decision-making in early stage PTC:
disease prognosis (including disease-related mortality and recur-
rence risks), the rationale (for or against RRA), the potential risks
and beneﬁts, the medical evidence uncertainty, the disease-follow-
up implications and reproductive considerations.
18 This DA has
been developed in plain English language by a multidisciplinary
team, based on reviews of the best available medical evidence.
18
Furthermore, the DA provides basic information, with the option
available for patients to retrieve supplemental detailed informa-
tion, including numerical data and references, if desired.
18 Web
Table 1. Some information needs related to consideration of radioactive iodine remnant ablation (RRA) (or no ablation), as identiﬁed by thyroid cancer
survivors
Information concepts of interest to patients* Examples of speciﬁc types of information
Disease prognosis (speciﬁcto pathologic stage of disease) General information on disease-related mortality and recurrence risks
(some patients preferring numerical data, others preferring
non-numerical general concepts) according to individual risk status
(i.e. pathologic stage of disease and other factors)
Clearly delineated treatment options A clear presentation of the choice of RRA or no RRA
Information about the disease-follow-up implications with each choice
A description of the treatment procedure of RRA
(with information on preparationand post-treatment precautions)
Treatment rationale An explanation of the rationale for or against RRA
(as appliedto the individual’s case)
The potential beneﬁts and risks of treatment options An explanation of evidence relating to the effect of RRA (or no RRA)
on long-term thyroid cancer outcomes (such as recurrence or mortality risk),
and any uncertainties of the medical evidence (such as lack
of long-termrandomized controlled trial data or conﬂicting results
of studies), with information speciﬁc for risk status (i.e. pathologic stage of disease)
An explanation of radioactive iodine treatment-related risks,
including potential short-term side effects or long-term risks.
A particular area of interest identiﬁed by patients is an
explanationof the potential risk of second primary
cancers after radioactive iodine treatment.
Current clinical guideline recommendations An explanation of current clinical practice guideline
recommendations, as applied to the individual case
Reproductive considerations
(if relevant to the individual patient)
If relevantto the individual, an explanation of radioactive
iodine treatment-related reproductive considerations
for the immediate and long-term future
(including any reassurances to long-termreproductive outcomes, if applicable)
*Table adapted from results of a qualitative study of thyroid cancer survivors (reference 10). The level of detail desired by individual patients relating to each
of the concepts is variable, and counselling should be tailored to the individualpatient’s preference.
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port groups are also provided in the DA programme. The content
of the DA is amenable to printing. We have previously reported
that a preliminary version of our DA was generally acceptable to lay
individuals, thyroid cancer survivors and endocrinologists,
although some minor revisions relating to format and wording
were suggested.
18 The preliminary version of the DA was revised, in
keeping with suggestions of participants in the initial usability
study, and testing of the revised version in a patient with thyroid
cancer population is described herein.
Testing of a thyroid cancer DA on the use of RRA in
patients with early stage PTC
Our objectives in the current study were to determine whether our
revised DA on RRA increases medical knowledge in patients
recently diagnosed with early stage PTC. We also examined the
usability of the DA in this population. We recruited individuals
aged 18 years or older who had a thyroidectomy since September
1, 2007 and whose surgical pathology reports conﬁrmed the pres-
ence of the following TNM stage of PTC: pT1a (multifocal if
<1 cm), pT1b, or pT2, N0 (or Nx), M0 (or Mx) (TNM stage, AJCC
VII
19), with no tall cell features (i.e. primary tumours were 4 cm or
less in diameter with no known positive lymph nodes and no
known distant metastases). Individuals with a single intra-thyroidal
papillary thyroid cancer measuring less than one centimetre in
diameter or those who had undergone only a hemithyroidectomy
(with no completion thyroidectomy) were not eligible for the study
because such patients aretypically not offered RRA.All participants
received usual counselling from their treating physicians and were
eligible whether or not they had received RRA. All participants
were required to be ﬂuent in written and spoken English and able
to read a computer screen. Participants were required to be taking
thyroid hormone treatment at the time of testing. The study was
approved by the University Health Network Research Ethics Board,
and all participants provided informed consent.
Study procedure and statistical analyses
Participants were tested between November of 2009 and February
of 2010. Demographic data were also collected from all partici-
pants. Participants self-navigated the DA website on a PC desktop
computer (using a secure website) in a research ofﬁce. Medical
knowledge of participants was evaluated before and after DA expo-
sure using a self-administered medical knowledge questionnaire.
18
The medical knowledge questionnaire includes 10 questions (true
or false) on the following topics: early stage PTC prognosis, RRA
treatment preparation and treatment procedure, potential radioac-
tive iodine treatment side effects, medical follow-up implications
of RRA or no RRA and current medical evidence on the impact of
RRA treatment on long-term thyroid cancer outcomes (scored by
number of correct responses out of 10, with a maximal score of 10)
(details of the development and validation of this questionnaire
available from the corresponding author by request).
18 Usability of
the DA was assessed by participants’ responses to an adapted
System Usability Scale (SUS) questionnaire for human–computer
interaction.
18,20 The adapted SUS questionnaire includes 10 ques-
tions on the ease of use, format and applicability of the DA (each
question scored on a Likert scale of 1–5 with 1 = strongly disagree
to 5 = strongly agree).
18
Descriptive data were presented as mean and standard deviation
(for continuous data) or number and percentage for categorical
data. A paired Student’s t-test was used to compare scores on the
medical knowledge questionnaire before and after exposure to the
DA. Unpaired Student’s t-tests were used to compare medical
knowledge questionnaire scores pre-DA for those who had previ-
ously received RRA compared with those who did not. The crite-
rion for statistical signiﬁcance was set at alpha = 0Æ05. Quantitative
statistical analyses were performed using PASW Statistics 18.0
(IBM, Chicago, IL, USA).
Results of testing the DA in patients with early stage PTC
The demographic characteristics of participants are shown in
Table 2. As expected for PTC, women comprised the largest per-
centage of participants (41/50, 82%). Most participants had a col-
lege or university or higher level education, and most described
themselves as very comfortable with computers (Table 1). The
mean time spent by participants in reviewing the website was
33 min (minimum 14, maximum 60 min). The mean score on the
Table 2. Demographic characteristics of participants testing the thyroid
cancer decision aid
Characteristic N (%)
Age (years)
18–30 5/50 (10Æ0)
31–40 11/50 (22Æ0)
41–50 18/50 (36Æ0)
51–60 12/50 (24Æ0)
61 or older 4/50 (8Æ0)
Female gender 41/50 (82Æ0)
Pathologic stage of disease (AJCC VI, TNM classiﬁcation)*
T1 23/50 (46Æ0)
T2 27/50 (54)
N0 37/50 (74)
Nx 13/60 (26Æ0)
M0 50/50 (100)
Highest level of education
High school 6/50 (12Æ0)
College or University 29/50 (58Æ0)
Postgraduate or professional degree 15/50 (30Æ0)
Frequency of computer use
Most days 46/50 (92Æ0)
Few times per week 3/50 (6Æ0)
Less than once a month 1/50 (2Æ0)
Comfort level with computers
Very comfortable 37/50 (74Æ0)
Somewhat comfortable 8/50 (16Æ0)
Comfortable 4/50 (8Æ0)
Uncomfortable 1/50 (2Æ0)
*Pathologic stageclassiﬁed using the American Joint Committee on Cancer
Staging Manual, 7th edition (reference 19).
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maximum score of 10) was 8Æ04 [standard deviation (SD) 1Æ43,
n = 50], prior to exposure to the DA. The mean score on the
knowledge questionnaire post-DA was 9Æ42 (SD 0Æ88). The DA sig-
niﬁcantly improved medical knowledge of patients (mean score
increase of 1Æ38 out of 10, SD 1Æ37) [t =7 Æ13, P <0 Æ001; degrees of
freedom (df) = 49]. On the adapted SUS questionnaire, partici-
pants generally strongly agreed (mean agreement scores of >4Æ5 out
of 5) with statement that the DA was easy to learn to navigate and
use (including printing information, or retrieving supplemental
information), that they felt conﬁdent using it, and that they
believed it would be used frequently by other patients. Participants
generally strongly disagreed (mean agreement scores <2 out of 5)
with the statements that the DA was unnecessarily complex, cum-
bersome, inconsistent, or would require technical support.
Discussion
In conclusion, the information needs of patients with early stage
papillary thyroid carcinoma considering radioactive iodine rem-
nant ablation are complex. We have found that a patient-directed
computerized decision aid, explaining the options of radioactive
iodine remnant ablation or no radioactive iodine remnant ablation
for early stage papillary thyroid carcinoma, improves patients’
medical knowledge after physician counselling. Furthermore, the
web-based format of the decision aid utilized in this study is
acceptable to patients. The decision aid tested herein was designed
to be used as an adjunct to individualized physician counselling, to
meet the information needs of patients who may desire supplemen-
tal web-based information. A limitation of the study was that most
participants were comfortable with using computers and well-edu-
cated, so the ﬁndings may not be generalizable to patients unfamil-
iar with computer technology. However, ultimately, the target
population for use of our decision aid are individuals seeking sup-
plemental web-based information sources, so we expect that such
individuals would be comfortable using computers. Another
important limitation of our study is that for most participants, the
decision to accept or reject radioactive iodine remnant ablation
had already been made prior to exposure to the decision aid, so we
could not examine the impact of the decision aid on the decision-
making process (including related psychosocial stress and cultural
factors), nor the ultimate decision. However, this was a pilot study,
utilized in the planning of a current randomized controlled trial, in
which we are comparing the medical knowledge of early stage pap-
illary thyroid carcinoma patients randomized to the decision aid
(with usual care) to compared to usual care alone.
21 In this trial, we
are also examining the impact of the decision aid on the ﬁnal deci-
sion, its rationale and satisfaction of patients and physicians.
21 In
the future, thyroid cancer treatment decision aids may become a
valuable adjunct in patient education, used to complement physi-
cian counselling.
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